News

Drug Briefing: Lenacapavir

Views: 47     Author: Unibest Industrial     Publish Time: 2024-06-24      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button


Query Drug:Lenacapavir

Query Time:2024-06-24 11:06:36

*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.


Related Diseases

Extra Information on Drug and Diseases

Similar Drugs

[Mechanism of Action] P-Glycoprotein Inhibitors

Source DAILYMED

[Mechanism of Action] P-Glycoprotein Inhibitors

Source FDASPL

[Mechanism of Action] Breast Cancer Resistance Protein Inhibitors

Source DAILYMED

[Mechanism of Action] Breast Cancer Resistance Protein Inhibitors

Source FDASPL

[Mechanism of Action] Cytochrome P450 3A Inhibitors

Source DAILYMED

[Mechanism of Action] Cytochrome P450 3A Inhibitors

Source FDASPL

[Mechanism of Action] Viral Envelope Wrapping Protein Inhibitors

Source MEDRT

[Mechanism of Action] HIV Capsid Inhibitors

Source DAILYMED

[Mechanism of Action] HIV Capsid Inhibitors

Source FDASPL

Similar Drugs

[Mechanism of Action] Viral Envelope Wrapping Protein Inhibitors

Source MEDRT

Orange Book

[Last update] 2024-05-21

Labelers

Lenacapavir's Innovator is GILEAD SCIENCES INC

Drug Products

The unique dosage forms from the innovator include:1. SOLUTION;SUBCUTANEOUS;2. TABLET;ORAL.

Index Route Brand Name Labeler Approval Date Dosage
1 SOLUTION;SUBCUTANEOUS SUNLENCA GILEAD SCIENCES INC Dec 22, 2022 EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)
2 TABLET;ORAL SUNLENCA GILEAD SCIENCES INC Dec 22, 2022 EQ 300MG BASE

Drug Patents

This drug still has 5 effective patents.

Patent Number Submission Date Expiration Date Drug Substance Patent? Drug Product Patent?
10654827 Jan 18, 2023 Aug 17, 2037

9951043 Jan 18, 2023 Feb 28, 2034 Y Y
10071985 Jan 18, 2023 Aug 17, 2037 Y Y
11267799 Jan 18, 2023 Aug 16, 2038 Y
11944611 Apr 23, 2024 Jun 4, 2041

Lenacapavir Patent Scope

Related Company's Product Pipelines

The innovator GILEAD SCIENCES INC's portolio contains products with the following 23 API(s): COBICISTAT, TENOFOVIR ALAFENAMIDE FUMARATE, COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE, SOFOSBUVIR, AMBRISENTAN, EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE, SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR, SOFOSBUVIR; VELPATASVIR, ADEFOVIR DIPIVOXIL, TENOFOVIR DISOPROXIL FUMARATE, ELVITEGRAVIR, EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE, CIDOFOVIR, REMDESIVIR, COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE, LEDIPASVIR; SOFOSBUVIR, EMTRICITABINE, LENACAPAVIR SODIUM, BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE, EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE, IDELALISIB, EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE, AZTREONAM


The above products are related to 57 diseases: HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Hepatitis C, Chronic, Hypertension, Pulmonary, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, Hepatitis B, Chronic, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, AIDS-Related Opportunistic Infections, Cytomegalovirus Retinitis, Virus Diseases, Coronavirus Infections, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Lymphoma, Non-Hodgkin, Leukemia, Lymphoid, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Cellulitis, Respiratory Tract Infections, Sepsis, Endometritis, Pseudomonas Infections, Urinary Tract Infections, Intraabdominal Infections


GILEAD SCIENCES INC_combined_chart_2024-06-24

Sankey Diagram for Gliead Science's portolio